ReNTox

Product Overview

ReNTox is a South Korean botulinum toxin type A product manufactured by PharmaResearch Bio Co., Ltd. Available in 100 Units and 200 Units, ReNTox contains Clostridium botulinum toxin type A, human serum albumin, and sodium chloride. Both formulations are supplied as white, lyophilized powder in transparent glass vials and are intended for professional medical use according to their applicable regulatory authorization.

ReNTox is a neuromodulator that temporarily inhibits acetylcholine release at susceptible peripheral nerve terminals, reducing neuromuscular signaling and muscle contraction.

PharmaResearch Bio manufactures the ReNTox product range for international markets. In South Korea, the company also holds a domestic marketing authorization for its 100-unit product, registered under the name Re N Tox Injection.

The 100U and 200U presentations contain the same principal ingredients but differ in total biological potency and excipient quantities.

Key Features

• Botulinum Toxin Type A: Contains a neuroactive protein that temporarily inhibits acetylcholine release, reducing neuromuscular transmission.
• Two Vial Strengths: Available as ReNTox 100 Units and ReNTox 200 Units, allowing professional buyers to distinguish between two labeled potency presentations.
• Albumin-Stabilized Formulation: Contains human serum albumin and sodium chloride as pharmaceutical excipients, with quantities corresponding to the selected vial strength.
• Lyophilized Preparation: Supplied as white, freeze-dried material in a transparent glass vial for preparation according to the authorized product instructions.
• South Korean Manufacturing: Manufactured by PharmaResearch Bio, a South Korean pharmaceutical company specializing in botulinum toxin products.

Composition & Specifications

ReNTox contains Clostridium botulinum toxin type A as its active ingredient, together with human serum albumin and sodium chloride.

The active ingredient is measured in biological potency units rather than milligrams. Each formulation contains a different total quantity of toxin activity and corresponding excipients.

Clostridium Botulinum Toxin Type A

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum.

Its pharmacological action involves the temporary inhibition of acetylcholine release at susceptible peripheral cholinergic nerve terminals.

Acetylcholine is a neurotransmitter involved in communication between motor neurons and skeletal muscle fibers.

By reducing acetylcholine release, botulinum toxin type A temporarily decreases neuromuscular transmission and the contraction of affected muscles.

ReNTox is available in two strengths:

• ReNTox 100U: Contains 100 Units of Clostridium botulinum toxin type A per vial.
• ReNTox 200U: Contains 200 Units of Clostridium botulinum toxin type A per vial.

The Units designation represents biological potency rather than the physical mass of the toxin protein.

Botulinum toxin potency units are product-specific and cannot automatically be converted between different commercial preparations.

Human Serum Albumin

Human serum albumin is a plasma-derived protein used as a stabilizing excipient in biological pharmaceutical formulations.

It helps maintain the physical stability of certain protein-based medicines during manufacturing, storage, and handling.

ReNTox 100U contains 0.5 mg human serum albumin per vial, while ReNTox 200U contains 1.0 mg.

Human serum albumin is a supporting ingredient rather than the active neuromodulating substance.

Because albumin is derived from human plasma, its inclusion is relevant to product-specific biological safety and manufacturing quality controls.

Sodium Chloride

Sodium chloride is a pharmaceutical excipient commonly used in injectable medicinal products.

It contributes to the physicochemical characteristics of the formulation.

ReNTox 100U contains 0.9 mg sodium chloride per vial, while ReNTox 200U contains 1.8 mg.

These quantities describe the original dried formulation and should not be confused with the composition of any separately supplied preparation solution.

The stated ingredient quantities describe the documented 100U and 200U formulations. Certain third-party listings contain conflicting excipient specifications, particularly for the 200U presentation. The original manufacturer-issued label and product-specific documentation take precedence.

How ReNTox Botulinum Toxin Type A Works

ReNTox temporarily reduces neuromuscular activity through the pharmacological action of botulinum toxin type A.

Acetylcholine and Muscle Contraction

Under normal physiological conditions, motor neurons release acetylcholine at the neuromuscular junction.

Acetylcholine binds to receptors on skeletal muscle cells, initiating electrical signals that contribute to muscle contraction.

SNAP-25 Cleavage

Botulinum toxin type A cleaves SNAP-25, a protein involved in the SNARE complex responsible for neurotransmitter vesicle fusion.

This process interferes with acetylcholine release, temporarily reducing signaling between motor neurons and affected muscles.

Temporary Neuromuscular Modulation

Reduced acetylcholine release leads to temporary relaxation or weakening of affected skeletal muscles.

In appropriately authorized aesthetic applications, this mechanism can temporarily improve the appearance of dynamic facial wrinkles associated with repeated muscle movement.

Neuromuscular function gradually recovers as biological processes restore neurotransmitter release.

These mechanisms are established for botulinum toxin type A. They do not demonstrate identical clinical potency, onset, duration, or safety between ReNTox and other botulinum toxin products.

Available ReNTox Variants

ReNTox is available in two documented strengths: ReNTox 100 Units and ReNTox 200 Units.

Both contain botulinum toxin type A with human serum albumin and sodium chloride. The principal differences are the total biological potency and excipient quantities per vial.

ReNTox 100 Units

ReNTox 100U contains 100 Units of Clostridium botulinum toxin type A, 0.5 mg human serum albumin, and 0.9 mg sodium chloride.

It is supplied as a white lyophilized preparation in a transparent glass vial.

The 100U presentation is documented in PharmaResearch Bio's international product portfolio.

The company's related domestic product, Re N Tox Injection 100 Units, received South Korean marketing authorization on February 1, 2024.

The documented domestic indication is the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65 years.

The domestic authorization should not automatically be interpreted as approval of every export-market presentation or indication.

ReNTox 200 Units

ReNTox 200U is the higher-strength presentation within the product family.

Each vial contains 200 Units of Clostridium botulinum toxin type A, 1.0 mg human serum albumin, and 1.8 mg sodium chloride.

The 200U formulation contains twice the total labeled toxin activity of the 100U presentation.

This difference does not mean that an individual unit of the 200U formulation is stronger or that clinical effects are necessarily longer-lasting.

ReNTox 200U is documented in the manufacturer's export product range and in South Korean regulatory records for export-oriented pharmaceutical products.

A separate South Korean domestic marketing authorization for ReNTox 200U has not been established from the reviewed manufacturer information.

ReNTox 100U and 200U contain the same principal ingredients in different total quantities. The two strengths must not be interpreted as interchangeable administration options without the applicable product-specific prescribing information.

Manufacturer & Product Development

ReNTox is manufactured by PharmaResearch Bio Co., Ltd., a South Korean pharmaceutical company involved in the development and production of botulinum toxin products.

PharmaResearch Bio is part of the PharmaResearch corporate group, which operates across pharmaceutical, regenerative medicine, and medical aesthetics businesses.

South Korean Manufacturing

PharmaResearch Bio manufactures its botulinum toxin products in South Korea.

The company announced Good Manufacturing Practice certification for its botulinum toxin manufacturing facility in 2019.

Manufacturing quality standards and regulatory authorization remain specific to the applicable facility, product, and destination market.

International Product Development

PharmaResearch Bio has supplied its ReNTox products to international markets through export-oriented pharmaceutical channels.

In August 2025, the company announced that Re N Tox had obtained marketing authorization from Thailand's Food and Drug Administration.

This authorization represents a product-specific regulatory development in Thailand and does not establish approval of every strength or indication in other countries.

Buyers should verify which ReNTox presentation is authorized in the destination market and whether the supplied packaging corresponds to the registered product.

Storage & Handling

South Korean pharmaceutical product records specify refrigerated storage at 2°C to 8°C for ReNTox 100U and 200U.

Both products are supplied as lyophilized preparations requiring appropriate professional handling under the original manufacturer's instructions.

• Refrigerated Storage: Store unopened vials at 2°C to 8°C.
• Temperature-Controlled Distribution: Maintain the validated refrigerated conditions during transportation and storage.
• Original Packaging: Keep the vial in its original sealed manufacturer packaging.
• Container Integrity: Inspect the vial and packaging for damage or evidence of compromised integrity.
• Product Traceability: Verify the product name, labeled potency, lot number, expiration date, and responsible manufacturer.

Handling After Preparation

The product information for the documented South Korean formulations specifies refrigerated handling after preparation.

The permitted period after preparation depends on the applicable registered product labeling.

Preparation, administration, and disposal must be performed according to the original instructions for use by appropriately qualified healthcare professionals.

Shelf Life

Commercial product information commonly identifies a shelf life of 36 months for ReNTox.

The definitive expiration date and validated storage period should be confirmed against the original manufacturer-issued label for each supplied batch.

The 2–8°C range is documented in South Korean pharmaceutical product records. Storage and handling instructions for a specific export-market presentation must be verified against its approved labeling.

Safety & Regulatory Considerations

ReNTox contains botulinum toxin type A, a potent neuroactive biological substance. Clinical use requires qualified medical supervision and compliance with the approved product information.

Potential Adverse Reactions

Adverse reactions associated with botulinum toxin type A products may include localized discomfort, swelling, bruising, headache, and unintended weakness of nearby muscles.

Depending on the circumstances of administration, additional effects can include eyelid drooping, facial asymmetry, and other functional changes.

Spread of Toxin Effects

Botulinum toxin effects may extend beyond the intended treatment area.

Serious complications can include generalized muscle weakness, difficulties swallowing or speaking, and respiratory impairment.

These reactions may be life-threatening and require immediate medical evaluation.

Contraindications and Precautions

Hypersensitivity to botulinum toxin type A or other formulation components is an important contraindication.

Certain neuromuscular disorders and medications affecting neuromuscular transmission can increase the risk of adverse reactions.

ReNTox also contains human serum albumin, making the product-specific precautions associated with human-derived biological excipients relevant.

Non-Interchangeable Potency Units

Botulinum toxin biological potency units are specific to each commercial product.

ReNTox units should not automatically be converted into equivalent quantities of BOTOX, Dysport, Xeomin, NABOTA, or other botulinum toxin preparations.

Identical numerical unit counts do not establish identical biological potency, diffusion behavior, duration of action, or clinical outcomes.

Regulatory Authorization

PharmaResearch Bio has manufactured ReNTox 100U and 200U for international markets.

South Korean regulatory records document export-oriented registrations for both strengths. The manufacturer's separate domestic Re N Tox 100U product received South Korean marketing authorization in February 2024.

PharmaResearch Bio also announced Thai regulatory authorization for Re N Tox in August 2025.

Historical regulatory records include administrative actions concerning earlier export-oriented ReNTox registrations. Therefore, the current legal status of each specific product, batch, and destination-market registration must be verified before procurement.

US FDA approval for ReNTox 100U or 200U has not been established.

Approval of another botulinum toxin type A medicine does not automatically extend to ReNTox.

This information is intended for professional product identification and commercial evaluation. It does not provide administration instructions, replace approved prescribing information, or authorize distribution outside applicable pharmaceutical regulations.

Frequently Asked Questions